title: Expression of β-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel.
abstract: OBJECTIVE
  To investigate the relationship between the expression of β-tubulin III and survivin in advanced breast cancers and chemotherapeutic effects of docetaxel.
  
  
  METHODS
  Clinical pathological data of 74 patients with advanced breast cancer were retrospectively analyzed after docetaxel chemotherapy. Expression of β-tubulin III and survivin was assessed by immunohistochemistry and analyzed with reference to therapeutical and adverse effects of docetaxel.
  
  
  RESULTS
  The positive expression rate of β-tubulin III was 38.1% (32/84), while that of survivin was 76.2% (64/84). The effective rate (complete response + partial response) was 52.4%. That for patients with the positive expression of β-tubulin III or/and survivin was significantly lower than for those with negative expression (P<0.05). There were significant differences in the non-progression of median diseases, 1-year and 2-year survival rates of between the patients with positive and negative expression (P<0.05). The main side effects were myelosuppression, alimentary canal response and alopecia, no differences being observed between groups.
  
  
  CONCLUSIONS
  The combined detection of β-tubulin III and survivin is a predictive index for chemotherapy effects of docetaxel in metastatic breast cancer.
authors.affiliation: Cancer Center, Third Affiliated Hospital, Wenzhou Medical College, Wenzhou, China.
authors.forename: Shao-Fei
authors.initials: SF
authors.lastname: Yuan
authors.forename: Lin-Jia
authors.initials: LJ
authors.lastname: Zhu
authors.forename: Wei-E
authors.initials: WE
authors.lastname: Zheng
authors.forename: Hua
authors.initials: H
authors.lastname: Chen
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Wu
authors.forename: Wu
authors.initials: W
authors.lastname: Zhang
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Sun
authors.forename: Wen-Jun
authors.initials: WJ
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D000077022:Survivin; D043823:Taxoids / Q000008:administration & dosage; D014404:Tubulin / Q000378:metabolism*
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; C498585:TUBB3 protein, human; D043823:Taxoids; D014404:Tubulin; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide